CERE-110

N/A

Report date: 2023/10/26 16:03:34

Base Information

Drug NameCERE-110
Drug Alias NameAAV-NGFNGF-AAVCERE-110
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionBeta-nerve growth factor stimulants
TargetsBeta-nerve growth factor
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California San Diego
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSangamo Therapeutics IncUniversity Of California San Diego
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A